We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10B
1-Year Est. Return
10.61%
This Fund
S&P 500
This Quarter
Est. Return
+3.55%
1 Year Est. Return
-10.61%
3 Year Est. Return
-7.98%
5 Year Est. Return
-20.78%
10 Year Est. Return
-1.56%
AUM
$13.6B
AUM Growth
+$9.23B
(+213%)
Cap. Flow
+$8.79B
Cap. Flow
% of AUM
64.78%
Top 10 Holdings %
Top 10 Hldgs %
99.94%
Holding
20
New
3
Increased
1
Reduced
3
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDLN
Medline Inc
MDLN
|
+$9.09B |
| 2 |
Invitation Homes
INVH
|
+$5.21M |
| 3 |
Robinhood
HOOD
|
+$439K |
| 4 |
Spyre Therapeutics
SYRE
|
+$251K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPRB
Spruce Biosciences
SPRB
|
+$306M |
| 2 |
SunPower Inc
SPWR
|
+$1.42M |
| 3 |
Exicure
XCUR
|
+$1.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.17% |
| 2 | Industrials | 32.3% |
| 3 | Technology | 0.26% |
| 4 | Real Estate | 0.19% |
| 5 | Communication Services | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDLN
1
Medline Inc
MDLN
$30.9B
| $9.04B | 66.65% |
+215,303,036
| New | +$9.09B |
|
|
SARO
2
StandardAero Inc
SARO
$9.7B
| $4.38B | 32.27% |
152,673,891
| – | – |
|
3
Phathom Pharmaceuticals
PHAT
$692M
| $58M | 0.43% |
3,496,808
| – | – |
|
|
PONY
4
Pony AI Inc
PONY
$3.54B
| $34.3M | 0.25% |
2,362,447
| – | – |
|
|
5
Invitation Homes
INVH
$18B
| $18.5M | 0.14% |
664,100
+186,600
| +39% | +$5.21M |
|
6
Getty Images
GETY
$183M
| $8.35M | 0.06% |
6,234,252
| – | – |
|
7
CubeSmart
CUBE
$9.41B
| $7.95M | 0.06% |
220,500
| – | – |
|
8
Q32 Bio
QTTB
$464M
| $3.62M | 0.03% |
1,102,741
| – | – |
|
|
SPRB
9
Spruce Biosciences
SPRB
$129M
| $3.3M | 0.02% |
38,620
-2,857,898
| -99% | -$306M |
|
10
Forward Air
FWRD
$654M
| $3.09M | 0.02% |
107,214
| – | – |
|
11
Jasper Therapeutics
JSPR
$23.6M
| $1.94M | 0.01% |
1,066,189
| – | – |
|
12
Adicet Bio
ACET
$74.7M
| $1.54M | 0.01% |
184,295
| – | – |
|
13
Krispy Kreme
DNUT
$576M
| $1.37M | 0.01% |
340,748
| – | – |
|
|
OKUR
14
OnKure Therapeutics
OKUR
$168M
| $772K | 0.01% |
269,895
| – | – |
|
15
N-able
NABL
$940M
| $701K | 0.01% |
93,732
| – | – |
|
|
16
SunPower Inc
SPWR
$53.8M
| $680K | 0.01% |
433,158
-825,812
| -66% | -$1.42M |
|
|
NCNA
17
NuCana
NCNA
$6.12M
| $480K | ﹤0.01% |
133,333
| – | – |
|
|
18
Robinhood
HOOD
$83.9B
| $382K | ﹤0.01% |
+3,376
| New | +$439K |
|
|
19
Spyre Therapeutics
SYRE
$9.25B
| $315K | ﹤0.01% |
+9,620
| New | +$251K |
|
|
20
Exicure
XCUR
$8.54M
| $305K | ﹤0.01% |
56,328
-225,308
| -80% | -$1.1M |
|
Similar funds
HRCM
RI
RA
HI
GI
MF
IIM
ACA
Carlyle Group's Q4 2025 Portfolio in Review
As of Q4 2025, Carlyle Group held 20 positions worth $13.6B, up 213% from $4.34B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Carlyle Group deployed $8.79B of net new capital in Q4 2025, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Medline Inc: 215,303,036 shares worth $9.04B.
By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 1.7% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Spruce Biosciences, an estimated $306M trimmed.
- Carlyle Group's largest Q4 2025 buy was Medline Inc: 215,303,036 shares worth $9.04B.
- Carlyle Group added most to Invitation Homes in Q4 2025, an estimated $5.21M increase.
- Carlyle Group's biggest Q4 2025 reduction was Spruce Biosciences, cutting an estimated $306M.
- Carlyle Group's ten largest holdings make up 100% of its $13.6B portfolio in Q4 2025.
- Carlyle Group opened 3 new positions and closed 0 in Q4 2025.
- Carlyle Group's portfolio value rose 213% quarter-over-quarter to $13.6B.
Based on Carlyle Group's 13F filing for Q4 2025, filed 13 Feb 2026.